Plexus (PLXS) is back in focus after Riverside Research highlighted a new partnership that targets reusable, modular hardware and software for intelligence and defense markets, anchored by the jointly developed Aegis R52L Enhanced Retransmission Device.

Plexus’s share price has risen 34.8% over the past 90 days and 76.22% year to date, contributing to a 1 year total shareholder return of 105.34%. This indicates that momentum has been building around recent contract wins and leadership share sales that are being viewed as routine.

If this kind of defense and secure-systems story has your attention, it may be a good moment to widen your radar with the 35 robotics and automation stocks

With Plexus trading close to its analyst price target after a strong run and reporting annual revenue and net income of US$4.31b and US$187.54m, you have to ask: is there still a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 27.3% Overvalued

With Plexus last closing at $268.26 against a narrative fair value of $210.80, the current price sits well above what that framework supports, raising questions about how much optimism is already reflected.

The company's increasing success in winning programs in high-margin, complex sectors such as healthcare/life sciences, aerospace, and defense (including strong defense pipeline in Europe and record sector wins), is shifting the revenue mix toward segments with higher pricing power and more stable, long-term contracts. This should positively impact both revenue consistency and net margin expansion.

Want to see what kind of revenue path and margin profile sits behind that outlook, and what future earnings multiple it leans on to reach $210.80?

Result: Fair Value of $210.80 (OVERVALUED)

However, there are still clear watchpoints, including demand pushouts in key sectors and high customer concentration. These factors could quickly pressure revenue and margins if sentiment shifts.

Next Steps

With sentiment clearly split between the upside case and the risk checklist, it makes sense to move quickly and weigh the data yourself using our 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Plexus has sharpened your interest, do not stop here. Use focused stock lists to quickly surface other opportunities that fit the way you like to invest.

• Target quality at a discount by scanning companies in the 47 high quality undervalued stocks that combine fundamentals with pricing that may not fully reflect them.
• Prioritise resilience by reviewing the 64 resilient stocks with low risk scores and concentrate on stocks with profiles designed to keep portfolio swings more controlled.
• Get ahead of the crowd by checking the screener containing 22 high quality undiscovered gems where solid fundamentals meet relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.